• Dr. Roscoe M. Moore Jr. has accepted a position on the Board of Directors of The Bio Diversity Group. The Bio Diversity Group is a company incorporated in 2009 in New York State as a vital advocate for promising small biotechnology companies in the HIV therapeutic arena. Since the economic collapse, many small biotechnology companies with potential novel treatments for HIV and associated pandemic co-morbidities have gone out of business and their technology lost in receivership. The Bio Diversity Group is dedicated to saving these companies and their technologies. Dr. Moore's professional and personal skills, interest and leadership are invaluable. Dr. Moore, former Assistant United States Surgeon General, serves as Senior Scientific Advisor for a number of privately held and publicly traded small biotechnology companies.

• Dr. Roscoe M. Moore Jr. has been appointed to the Scientific Advisory Board of Cannabis Science Incorporated. Cannabis Science is a publicly traded company based in Colorado Springs, Colorado. Cannabis Science is at the forefront of cannabinoid research and development for unmet medical needs. The Company is working to commercialize phytocannabinoid-based pharmaceutical products in the treatment of HIV/AIDS based upon the recent discovery by the Mount Sinai School of Medicine that phytocannabinoids inhibit a key HIV gene which controls the replication of the virus, and for the topical treatment of basal and squamous cell carcinomas. Dr. Moore is the former Assistant United States Surgeon General, and he has extensive expertise in the design and implementation of clinical protocols used in research.

• Dr. Roscoe M. Moore Jr. has been invited by ImmunoClin to serve as Chairman of its Board of Directors. ImmunoClin is a London based biotechnology company with laboratories in Paris. ImmunoClin has therapeutic candidates for HIV and diagnostics for bacterial and viral pathogens, cardiovascular disease risk and Alzheimer's disease risk. Its combination of leading industrial drug development experience, academic expertise and dedicated resources allow ImmunoClin to provide unique solutions for immunological diseases. Dr. Moore, former Assistant United States Surgeon General, has considerable leadership skills, experience and expertise to guide ImmunoClin into the future.